A new study, XIENCE Short DAPT, will evaluate whether three months of dual antiplatelet therapy (DAPT) is non-inferior to the standard duration of DAPT (12 months) in high bleeding risk patients who have undergone percutaneous coronary intervention (PCI) with an everolimus-eluting stent (Xience, Abbott Vascular). The study will enrol approximately 2,000 patients at 100 sites in the USA and Asia.
XIENCE Short DAPT is a prospective, multicentre, open label, single-arm, non-randomised study. The primary endpoint is non-inferior rates of myocardial infarction or death in high-bleeding risk patients. Secondary endpoints include evaluation of the extent and severity of bleeding rates, stent thrombosis, stroke, revascularisation, myocardial infarction and death.
Principal investigator Roxana Mehran (Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, USA) says: “Limiting the duration of blood-thinning medicine from 12 months to three months is particularly important for people at higher risk of bleeding due to factors such as older age, anaemia, and renal disease. The results of this study will help determine if doctors can safely reduce the amount of time that high bleeding-risk patients must take blood thinning medication after receiving a Xience stent to unblock coronary arteries.”
